PLRZ

Polyrizon Ltd.

Polyrizon Ltd. (PLRZ) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (C+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -0.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 0.6%
Price Return 12M 117.7%
Catalyst Signal 0.00
Market Cap $26.8M
TTM Revenue N/A
Price / Sales N/A
ROE -21.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C+ (2.5) B- (3.0) C+ (2.6) C+ (2.6) C+ (2.7)
2026-11-07 C+ (2.5) C+ (2.5) B- (3.0) C (2.3) C+ (2.7) C+ (2.6)
2026-10-31 C+ (2.5) C+ (2.5) C- (2.1) C+ (2.6) C+ (2.7) C (2.5)
2026-10-24 C+ (2.5) C+ (2.5) C- (2.1) C- (1.9) C+ (2.6) C (2.3)
2026-10-17 C+ (2.5) C+ (2.5) C- (2.1) C (2.4) C+ (2.6) C (2.4)
Page 1 of 4